Evidence map›Paper›PMID 39087355›Full record

Trial reportCirculation. Heart failure2024

Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial.

Catherine G Ireland, Danielle S Burstein, Sharlene M Day, Anna Axelsson Raja, Mark W Russell, Kenneth G Zahka, Alexandre Pereira, Charles E Canter, Richard G Bach, Matthew T Wheeler and 14 more

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Circulation. Heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01912534 (Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01912534 phase2completednot on this map

Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM

TypeinterventionalSponsorCarelon ResearchRan2014 to 2019Enrolled211ConditionsHypertrophic CardiomyopathyArmsValsartan, Placebo
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. ANMCO position paper 'Hypertrophic cardiomyopathy: from diagnosis to treatment'.European heart journal supplements : journal of the European Society of Cardiology · 2025
    Article
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Catherine G IrelandBrigham and Women's Hospital, Harvard Medical School, Boston, MA (C.G.I., E.J.O., B.C., C.Y.H.).
Danielle S BursteinUniversity of Vermont Larner School of Medicine, Burlington (D.S.B.).
Sharlene M DayUniversity of Pennsylvania Perelman School of Medicine, Philadelphia (S.M.D., A.T.O.).ORCID 0000-0001-9802-7188
Anna Axelsson RajaCopenhagen University Hospital, Rigshospitalet, Denmark (A.A.R., H.B.).ORCID 0000-0001-8665-3309
Mark W RussellUniversity of Michigan, Ann Arbor (M.W.R.).ORCID 0000-0003-4855-9260
Kenneth G ZahkaCleveland Clinic Foundation, OH (K.G.Z.).
Alexandre PereiraHeart Institute, University of Sao Paulo Medical School, Brazil (A.P.).
Charles E CanterWashington University School of Medicine, St. Louis, MO (C.E.C., R.G.B.).ORCID 0000-0002-0007-7337
Richard G BachWashington University School of Medicine, St. Louis, MO (C.E.C., R.G.B.).
Matthew T WheelerStanford University School of Medicine, Palo Alto, CA (M.T.W.).ORCID 0000-0001-8721-3022
Joseph W RossanoChildren's Hospital of Philadelphia, PA (J.W.R., K.Y.L.).ORCID 0000-0002-8284-0673
Anjali T OwensUniversity of Pennsylvania Perelman School of Medicine, Philadelphia (S.M.D., A.T.O.).ORCID 0000-0002-9669-8495
Henning BundgaardCopenhagen University Hospital, Rigshospitalet, Denmark (A.A.R., H.B.).ORCID 0000-0002-0563-7049
Luisa MestroniUniversity of Colorado Anschutz Medical Campus, Aurora (L.M., M.R.G.T.).ORCID 0000-0003-1116-2286
Matthew R G TaylorUniversity of Colorado Anschutz Medical Campus, Aurora (L.M., M.R.G.T.).ORCID 0000-0001-9043-0810
Amit R PatelUniversity of Virginia, Charlottesville (A.R.P.).ORCID 0000-0001-7621-6463
Ivan WilmotCincinnati Children's Hospital Medical Center, OH (I.W.).
Jonathan H SoslowVanderbilt University Medical Center, Nashville, TN (J.H.S.).ORCID 0000-0001-9194-5330
Jason R BeckerUniversity of Pittsburgh, PA (J.R.B.).ORCID 0000-0002-2107-8179
Ilya GivertsMassachusetts General Hospital, Boston (I.G.).ORCID 0000-0002-9363-9748
E John OravBrigham and Women's Hospital, Harvard Medical School, Boston, MA (C.G.I., E.J.O., B.C., C.Y.H.).ORCID 0000-0002-8886-7252
Brian ClaggettBrigham and Women's Hospital, Harvard Medical School, Boston, MA (C.G.I., E.J.O., B.C., C.Y.H.).ORCID 0000-0002-4215-9218
Kimberly Y Lin *Children's Hospital of Philadelphia, PA (J.W.R., K.Y.L.).ORCID 0000-0003-1582-9797
Carolyn Y Ho *Brigham and Women's Hospital, Harvard Medical School, Boston, MA (C.G.I., E.J.O., B.C., C.Y.H.).

Funding

Using Genetics For Early Phenotyping & Prevention of Hypertrophic CardiomyopathyP50HL112349 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI HO, CAROLYN Y, SEIDMAN, CHRISTINE E · 2012 to 2017
$11.2M
Noninvasive Cardiovascular Imaging Research Training ProgramT32HL094301 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI Marcelo F DI CARLI · 2010 to 2026
$7.8M
NHLBI NIH HHS P50 HL112349NHLBI NIH HHS T32 HL094301
6 · The paper itself

Abstract

backgroundThe health-related quality of life (HRQOL) and cardiopulmonary exercise testing (CPET) performance of individuals with subclinical and early stage hypertrophic cardiomyopathy (HCM) have not been systematically studied. Improved understanding will inform the natural history of HCM and factors influencing well-being.

methodsVANISH trial (Valsartan for Attenuating Disease Evolution in Early Sarcomeric HCM) participants with early stage sarcomeric HCM (primary analysis cohort) and subclinical HCM (sarcomere variant without left ventricular hypertrophy comprising the exploratory cohort) who completed baseline and year 2 HRQOL assessment via the pediatric quality of life inventory and CPET were studied. Metrics correlating with baseline HRQOL and CPET performance were identified. The impact of valsartan treatment on these measures was analyzed in the early stage cohort.

resultsTwo hundred participants were included: 166 with early stage HCM (mean age, 23±10 years; 40% female; 97% White; and 92% New York Heart Association class I) and 34 subclinical sarcomere variant carriers (mean age, 16±5 years; 50% female; and 100% White). Baseline HRQOL was good in both cohorts, although slightly better in subclinical HCM (composite pediatric quality of life score 84.6±10.6 versus 90.2±9.8;

conclusionsFunctional capacity can be impaired in young, healthy people with early stage HCM, despite New York Heart Association class I status and good HRQOL. Peak oxygen uptake was similarly decreased in subclinical HCM despite normal left ventricular wall thickness and excellent HRQOL. Valsartan improved physical pediatric quality of life scores but did not significantly impact CPET performance. Further studies are needed for validation and to understand how to improve patient experience. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01912534.

Indexed as

Cardiomyopathy, HypertrophicExercise TestExercise ToleranceQuality of LifeValsartanAdolescentAdultAngiotensin II Type 1 Receptor BlockersChildFemaleHumansMaleTreatment OutcomeYoung AdultAngiotensin II Type 1 Receptor BlockersValsartancardiomyopathy, hypertrophicexercise testfunctional statuspsychological well-beingquality of life

Identifiers

PMID39087355
PMCPMC11335449

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.